KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Net Margin (2017 - 2025)

Historic Net Margin for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to 120.61%.

  • Aquestive Therapeutics' Net Margin fell 356200.0% to 120.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 524.32%, marking a year-over-year increase of 5840700.0%. This contributed to the annual value of 4378.67% for FY2024, which is 43631100.0% down from last year.
  • Aquestive Therapeutics' Net Margin amounted to 120.61% in Q3 2025, which was down 356200.0% from 135.44% recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Net Margin registered a high of 72.46% during Q1 2023, and its lowest value of 618.35% during Q2 2021.
  • Moreover, its 5-year median value for Net Margin was 109.36% (2022), whereas its average is 128.6%.
  • As far as peak fluctuations go, Aquestive Therapeutics' Net Margin skyrocketed by 4145800bps in 2022, and later tumbled by -1788900bps in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Net Margin (Quarter) stood at 261.28% in 2021, then skyrocketed by 56bps to 115.63% in 2022, then skyrocketed by 47bps to 61.42% in 2023, then soared by 162bps to 38.17% in 2024, then tumbled by -416bps to 120.61% in 2025.
  • Its Net Margin stands at 120.61% for Q3 2025, versus 135.44% for Q2 2025 and 262.96% for Q1 2025.